Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
المؤلفون المشاركون
Smith, Daryn
Jacobs, John
Mulrenan, Heather
Lin, Ho-Sheng
Heilbrun, Lance K.
Yoo, George
Kafri, Zyad
Kucuk, Omer
Sukari, Ammar
المصدر
العدد
المجلد 2012، العدد 2012 (31 ديسمبر/كانون الأول 2012)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2012-05-10
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
Purpose.
To explore the safety and efficacy of gemcitabine and docetaxel (GEMDOC) in previously treated patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Patients and Methods.
Patients with advanced SCCHN previously pretreated with one or two lines of palliative chemotherapy were treated with gemcitabine and docetaxel until disease progression.
Results.
Thirty-six patients were enrolled, and 29 were response evaluable.
16 (55%) experienced clinical benefit (response or stable disease).
Six (21%) patients achieved partial response (PR), none achieved complete response (CR), and the overall response rate (ORR) was 21% (95% CI: 0.10–0.38).
Ten (28%) patients had stable disease.
The median response duration (RD) for the 6 PR patients was 3.2 months (80% CI: 2.0–6.1 months).
Median overall survival was 4.2 months (95% CI: 2.4–7.0 months).
Among the 33 treated patients: 13 (39%) patients had grade 3-4 anemia, 10 (30%) had grade 3-4 neutropenia.
Conclusion.
The study drugs were relatively safe, and the clinical benefit (PR + SD) rate was 55%.
However, the efficacy objective for this regimen was not met.
Given the good safety profile, further investigation of this regimen with the addition of a targeted agent may lead to better efficacy.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Kafri, Zyad& Heilbrun, Lance K.& Sukari, Ammar& Yoo, George& Jacobs, John& Lin, Ho-Sheng…[et al.]. 2012. Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. ISRN Oncology،Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-450587
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Kafri, Zyad…[et al.]. Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. ISRN Oncology No. 2012 (2012), pp.1-6.
https://search.emarefa.net/detail/BIM-450587
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Kafri, Zyad& Heilbrun, Lance K.& Sukari, Ammar& Yoo, George& Jacobs, John& Lin, Ho-Sheng…[et al.]. Phase II Study of Gemcitabine and Docetaxel Combination in Patients with Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. ISRN Oncology. 2012. Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-450587
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-450587
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر